371 related articles for article (PubMed ID: 34753775)
21. Evaluation of the Therapeutic Potential of a HER3-Binding Affibody Construct TAM-HER3 in Comparison with a Monoclonal Antibody, Seribantumab.
Orlova A; Bass TZ; Rinne SS; Leitao CD; Rosestedt M; Atterby C; Gudmundsdotter L; Frejd FY; Löfblom J; Tolmachev V; Ståhl S
Mol Pharm; 2018 Aug; 15(8):3394-3403. PubMed ID: 29995421
[TBL] [Abstract][Full Text] [Related]
22. DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors.
Li X; Yao J; Qu C; Luo L; Li B; Zhang Y; Zhu Z; Qiu Y; Hua H
J Transl Med; 2024 Apr; 22(1):362. PubMed ID: 38632563
[TBL] [Abstract][Full Text] [Related]
23. A monoclonal antibody to the human HER3 receptor inhibits Neuregulin 1-beta binding and co-operates with Herceptin in inhibiting the growth of breast cancer derived cell lines.
Blackburn E; Zona S; Murphy ML; Brown IR; Chan SK; Gullick WJ
Breast Cancer Res Treat; 2012 Jul; 134(1):53-9. PubMed ID: 22169894
[TBL] [Abstract][Full Text] [Related]
24. NRG1-dependent activation of HER3 induces primary resistance to trastuzumab in HER2-overexpressing breast cancer cells.
Yang L; Li Y; Shen E; Cao F; Li L; Li X; Wang X; Kariminia S; Chang B; Li H; Li Q
Int J Oncol; 2017 Nov; 51(5):1553-1562. PubMed ID: 29048656
[TBL] [Abstract][Full Text] [Related]
25. Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands.
Carrión-Salip D; Panosa C; Menendez JA; Puig T; Oliveras G; Pandiella A; De Llorens R; Massaguer A
Int J Oncol; 2012 Sep; 41(3):1128-38. PubMed ID: 22684500
[TBL] [Abstract][Full Text] [Related]
26. The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells.
Kawakami H; Okamoto I; Yonesaka K; Okamoto K; Shibata K; Shinkai Y; Sakamoto H; Kitano M; Tamura T; Nishio K; Nakagawa K
Oncotarget; 2014 Dec; 5(23):11847-56. PubMed ID: 25474137
[TBL] [Abstract][Full Text] [Related]
27. Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers.
Garrett JT; Sutton CR; Kurupi R; Bialucha CU; Ettenberg SA; Collins SD; Sheng Q; Wallweber J; Defazio-Eli L; Arteaga CL
Cancer Res; 2013 Oct; 73(19):6013-23. PubMed ID: 23918797
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of Tumor Cell Growth and Cancer Stem Cell Expansion by a Bispecific Antibody Targeting EGFR and HER3.
Rau A; Lieb WS; Seifert O; Honer J; Birnstock D; Richter F; Aschmoneit N; Olayioye MA; Kontermann RE
Mol Cancer Ther; 2020 Jul; 19(7):1474-1485. PubMed ID: 32430487
[TBL] [Abstract][Full Text] [Related]
29. NRG-1 Stimulates Serum DJ-1 Increase in Breast Cancers.
Wang Y; Zhang Y; Lu Q; Wang Y; Sun X; Zhang S
Pathol Oncol Res; 2019 Jan; 25(1):71-79. PubMed ID: 28963699
[TBL] [Abstract][Full Text] [Related]
30. Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer.
Shin DH; Jo JY; Han JY
Mol Cancer Ther; 2018 Sep; 17(9):2024-2033. PubMed ID: 29959202
[TBL] [Abstract][Full Text] [Related]
31. Targeting and suppression of HER3-positive breast cancer by T lymphocytes expressing a heregulin chimeric antigen receptor.
Zuo BL; Yan B; Zheng GX; Xi WJ; Zhang X; Yang AG; Jia LT
Cancer Immunol Immunother; 2018 Mar; 67(3):393-401. PubMed ID: 29127433
[TBL] [Abstract][Full Text] [Related]
32. NRG1/ERBB3 Pathway Activation Induces Acquired Resistance to XPO1 Inhibitors.
Miyake TM; Pradeep S; Bayraktar E; Stur E; Handley KF; Wu SY; Rodriguez-Aguayo C; Lee JS; Lopez-Berestein G; Coleman RL; Sood AK
Mol Cancer Ther; 2020 Aug; 19(8):1727-1735. PubMed ID: 32499298
[TBL] [Abstract][Full Text] [Related]
33. RG7116, a therapeutic antibody that binds the inactive HER3 receptor and is optimized for immune effector activation.
Mirschberger C; Schiller CB; Schräml M; Dimoudis N; Friess T; Gerdes CA; Reiff U; Lifke V; Hoelzlwimmer G; Kolm I; Hopfner KP; Niederfellner G; Bossenmaier B
Cancer Res; 2013 Aug; 73(16):5183-94. PubMed ID: 23780344
[TBL] [Abstract][Full Text] [Related]
34. ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells.
Choi BK; Fan X; Deng H; Zhang N; An Z
Cancer Med; 2012 Aug; 1(1):28-38. PubMed ID: 23342251
[TBL] [Abstract][Full Text] [Related]
35. Patient derived organoids to model rare prostate cancer phenotypes.
Puca L; Bareja R; Prandi D; Shaw R; Benelli M; Karthaus WR; Hess J; Sigouros M; Donoghue A; Kossai M; Gao D; Cyrta J; Sailer V; Vosoughi A; Pauli C; Churakova Y; Cheung C; Deonarine LD; McNary TJ; Rosati R; Tagawa ST; Nanus DM; Mosquera JM; Sawyers CL; Chen Y; Inghirami G; Rao RA; Grandori C; Elemento O; Sboner A; Demichelis F; Rubin MA; Beltran H
Nat Commun; 2018 Jun; 9(1):2404. PubMed ID: 29921838
[TBL] [Abstract][Full Text] [Related]
36. Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function.
Garrett JT; Sutton CR; Kuba MG; Cook RS; Arteaga CL
Clin Cancer Res; 2013 Feb; 19(3):610-9. PubMed ID: 23224399
[TBL] [Abstract][Full Text] [Related]
37. Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells.
Kang JC; Poovassery JS; Bansal P; You S; Manjarres IM; Ober RJ; Ward ES
MAbs; 2014; 6(2):340-53. PubMed ID: 24492289
[TBL] [Abstract][Full Text] [Related]
38. Response to ERBB3-Directed Targeted Therapy in
Drilon A; Somwar R; Mangatt BP; Edgren H; Desmeules P; Ruusulehto A; Smith RS; Delasos L; Vojnic M; Plodkowski AJ; Sabari J; Ng K; Montecalvo J; Chang J; Tai H; Lockwood WW; Martinez V; Riely GJ; Rudin CM; Kris MG; Arcila ME; Matheny C; Benayed R; Rekhtman N; Ladanyi M; Ganji G
Cancer Discov; 2018 Jun; 8(6):686-695. PubMed ID: 29610121
[No Abstract] [Full Text] [Related]
39. Overexpression of secretory phospholipase A2-IIa supports cancer stem cell phenotype via HER/ERBB-elicited signaling in lung and prostate cancer cells.
Lu S; Dong Z
Int J Oncol; 2017 Jun; 50(6):2113-2122. PubMed ID: 28440478
[TBL] [Abstract][Full Text] [Related]
40. Pleiotropic Mechanisms Drive Endocrine Resistance in the Three-Dimensional Bone Microenvironment.
Dhimolea E; de Matos Simoes R; Kansara D; Weng X; Sharma S; Awate P; Liu Z; Gao D; Mitsiades N; Schwab JH; Chen Y; Jeselsohn R; Culhane AC; Brown M; Georgakoudi I; Mitsiades CS
Cancer Res; 2021 Jan; 81(2):371-383. PubMed ID: 32859606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
